ABIOMED, Inc. is a provider of medical devices, which provides circulatory support and oxygenation. The Company develops, manufactures and markets its products, which are designed to improve blood flow and/or performing the pumping function of the heart. Its products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists and in the heart surgery suite by cardiac surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. Its operating segment includes the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. Its existing products include Impella 2.5, Impella CP, Impella 5.0 and Impella LD. The Impella 2.5 device is a percutaneous micro heart pump with an integrated motor and sensors. The Impella CP device provides blood flow of approximately one liter more per minute than the Impella 2.5 device.
During the most recent quarter, 40K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.